Mass cytometry on PBMCs from patients with chronic lympocytic leukaemia (CLL)

Quantify apoptosis by mass cytometry in CLL PBMCs treated with forodesine + deoxyguanosine. Samples were divided into two groups: with SAMHD1 mutations and without SAMHD1 mutation. No SAMHD1 protein was detected in SAMHD1 mutated group, confirming loss-of-function mutation.
Conclusion:
Only leukaemic cells that did not express SAMHD1 (harbouring SAMHD1 mutation) showed increased levels of cleaved-PARP and cleaved-CASPASE3.
Notes:
The leukaemic population in PBMCs could be divided into active and inactive cells. Active cells are characterised by active MAPK, NF-kb and JAK/STAT signalling pathways, as shown by the phosphorylated proteins of that pathway identified by mass cytometry. File names correspond to patient ID referred to in our manuscript https://www.biorxiv.org/content/10.1101/2020.02.17.951517v1.full . H1, H2 and H3 are healthy donors. Samples were concatenated and debarcoded